CN1123571C - 用作nmda受体拮抗剂的1－(3－杂芳基丙基－或－丙－2－烯基)－4－苄基哌啶 - Google Patents

用作nmda受体拮抗剂的1－(3－杂芳基丙基－或－丙－2－烯基)－4－苄基哌啶 Download PDF

Info

Publication number
CN1123571C
CN1123571C CN99804190A CN99804190A CN1123571C CN 1123571 C CN1123571 C CN 1123571C CN 99804190 A CN99804190 A CN 99804190A CN 99804190 A CN99804190 A CN 99804190A CN 1123571 C CN1123571 C CN 1123571C
Authority
CN
China
Prior art keywords
fluorobenzyl
acid
piperidin
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN99804190A
Other languages
English (en)
Chinese (zh)
Other versions
CN1293673A (zh
Inventor
H·普鲁彻
A·巴伯
J·莱布洛克
G·巴托泽克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1293673A publication Critical patent/CN1293673A/zh
Application granted granted Critical
Publication of CN1123571C publication Critical patent/CN1123571C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN99804190A 1998-03-20 1999-03-11 用作nmda受体拮抗剂的1－(3－杂芳基丙基－或－丙－2－烯基)－4－苄基哌啶 Expired - Fee Related CN1123571C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19812331.0 1998-03-20
DE19812331A DE19812331A1 (de) 1998-03-20 1998-03-20 Piperidinderivate

Publications (2)

Publication Number Publication Date
CN1293673A CN1293673A (zh) 2001-05-02
CN1123571C true CN1123571C (zh) 2003-10-08

Family

ID=7861717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99804190A Expired - Fee Related CN1123571C (zh) 1998-03-20 1999-03-11 用作nmda受体拮抗剂的1－(3－杂芳基丙基－或－丙－2－烯基)－4－苄基哌啶

Country Status (22)

Country Link
US (1) US6548516B1 (https=)
EP (1) EP1068202B1 (https=)
JP (1) JP4451565B2 (https=)
KR (1) KR20010042047A (https=)
CN (1) CN1123571C (https=)
AR (1) AR014747A1 (https=)
AT (1) ATE416173T1 (https=)
AU (1) AU747900B2 (https=)
BR (1) BR9908902A (https=)
CA (1) CA2324339C (https=)
DE (2) DE19812331A1 (https=)
DK (1) DK1068202T3 (https=)
ES (1) ES2316184T3 (https=)
HU (1) HUP0101220A3 (https=)
ID (1) ID26125A (https=)
NO (1) NO20004668L (https=)
PL (1) PL342732A1 (https=)
PT (1) PT1068202E (https=)
RU (1) RU2217429C2 (https=)
SK (1) SK13692000A3 (https=)
WO (1) WO1999048891A1 (https=)
ZA (1) ZA992191B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2409006A1 (en) 2000-05-31 2001-12-06 Warner-Lambert Company Biciclic cyclohexylamines and their use as nmda receptor antogonists
JP2003535851A (ja) * 2000-06-06 2003-12-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 二環式シクロヘキシルアミン類およびそれらのｎｍｄａ受容体アンタゴニストとしての使用
JP2004516295A (ja) 2000-12-21 2004-06-03 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー サブタイプ選択的なｎ−メチル−ｄ−アスパラギン酸拮抗薬としてのピペリジン誘導体
MXPA02002749A (es) 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
DE10248067A1 (de) * 2002-10-07 2004-04-15 Proteosys Ag Heteroarylpropyl-Piperazine und Heteroarylpropyl-Piperidine
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
CA2784119A1 (en) 2009-12-15 2011-06-23 Neurop, Inc. Compounds for the treatment of neurologic disorders
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
CN102133198B (zh) * 2011-03-09 2012-02-08 北京四环科宝制药有限公司 一种酒石酸艾芬地尔冻干粉针剂及其制备方法
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CN103965188A (zh) * 2013-01-29 2014-08-06 中山大学 含硒多奈哌齐类似物
RS61688B1 (sr) 2015-04-29 2021-05-31 Janssen Pharmaceutica Nv Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora
US10604484B2 (en) * 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JP3084729B2 (ja) * 1990-06-15 2000-09-04 横河電機株式会社 デジタルオシロスコープ
TW281670B (https=) * 1993-09-02 1996-07-21 Hoffmann La Roche
FR2717810B1 (fr) * 1994-03-22 1996-04-26 Adir Nouvelles aminoalkyl benzoxazolinones et benzothiazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1996002250A1 (en) 1994-07-20 1996-02-01 Acea Pharmaceuticals Inc. Haloperidol analogs and the use thereof
ATE174915T1 (de) 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat

Also Published As

Publication number Publication date
EP1068202B1 (de) 2008-12-03
ATE416173T1 (de) 2008-12-15
WO1999048891A1 (de) 1999-09-30
JP4451565B2 (ja) 2010-04-14
HUP0101220A2 (hu) 2002-05-29
SK13692000A3 (sk) 2001-02-12
AU3410599A (en) 1999-10-18
JP2002507613A (ja) 2002-03-12
BR9908902A (pt) 2000-11-28
US6548516B1 (en) 2003-04-15
EP1068202A1 (de) 2001-01-17
NO20004668D0 (no) 2000-09-19
CA2324339C (en) 2010-01-12
AU747900B2 (en) 2002-05-30
HUP0101220A3 (en) 2003-08-28
PL342732A1 (en) 2001-07-02
NO20004668L (no) 2000-09-19
RU2217429C2 (ru) 2003-11-27
DE59914921D1 (de) 2009-01-15
CA2324339A1 (en) 1999-09-30
PT1068202E (pt) 2009-03-06
ZA992191B (en) 1999-09-29
KR20010042047A (ko) 2001-05-25
DE19812331A1 (de) 1999-09-23
ID26125A (id) 2000-11-23
CN1293673A (zh) 2001-05-02
AR014747A1 (es) 2001-03-28
DK1068202T3 (da) 2009-03-16
ES2316184T3 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
CN1123571C (zh) 用作nmda受体拮抗剂的1－(3－杂芳基丙基－或－丙－2－烯基)－4－苄基哌啶
EP1425272B1 (en) Optical isomers of an iloperidone metabolite
CN1064358C (zh) 苄基哌啶衍生物
US5929094A (en) Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
CN1606554B (zh) β-内酰胺后叶加压素V1a拮抗剂
CN1628104A (zh) 喹唑啉酮衍生物及其作为cb激动剂的应用
CN1177847C (zh) 作为5－ht2a拮抗剂的噁唑烷酮类化合物
CA2615813C (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
CN1768053A (zh) 吡唑化合物
CN1805953A (zh) 用作血清素再摄取抑制剂的吲哚衍生物
CN1768056A (zh) 色烯酮吲哚
WO1998017276A1 (en) Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
CN1751040A (zh) 作为抗抑郁剂和抗焦虑剂的苯并呋喃氧基乙基胺
JP2002326988A (ja) サブタイプの選択的なｎ−メチル−ｄ−アスパルテート拮抗薬としてのシクロヘキシルアミン誘導体
CN100336813C (zh) 作为mGluR1增强剂的唑
CN1304409A (zh) 用于治疗抑郁症的吲哚－3－基－环己胺衍生物(5－ht1受体拮抗剂)
CN1956959A (zh) 治疗化合物：吡啶n氧化物支架
CN1729187A (zh) 取代的苯并二氧杂环庚烯
CN1135228C (zh) 用于治疗抑郁症的n-芳氧基乙基-吲哚基-烷基胺
HK1066536B (en) Optical isomers of an iloperidone metabolite
HK1156309B (en) Optical isomers of an iloperidone metabolite
CZ2000820A3 (cs) Derivát piperidinylmethyloxazolidinonu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje
HK1093729A1 (en) Benzisoxazoles
HK1114083A (en) Thienopyridinone compounds and methods of treatment
CN1187811A (zh) 1－[ω－(3,4－二氢－2－萘基)烷基]环状胺衍生物、其制造方法及含有该化合物的医药组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee